Stromal-Derived NRG1 Enables Oncogenic KRAS Bypass in Pancreas Cancer

Authors

Jincheng Han
Jiaqian Xu
Yonghong Liu
Shaoheng Liang
Kyle A LaBella
Deepavali Chakravarti
Denise J Spring
Yan Xia
Ronald A DePinho

Publication Date

9-1-2023

Journal

Genes Development

Abstract

Activating KRAS mutations (KRAS*) in pancreatic ductal adenocarcinoma (PDAC) drive anabolic metabolism and support tumor maintenance. KRAS* inhibitors show initial antitumor activity followed by recurrence due to cancer cell-intrinsic and immune-mediated paracrine mechanisms. Here, we explored the potential role of cancer-associated fibroblasts (CAFs) in enabling KRAS* bypass and identified CAF-derived NRG1 activation of cancer cell ERBB2 and ERBB3 receptor tyrosine kinases as a mechanism by which KRAS*-independent growth is supported. Genetic extinction or pharmacological inhibition of KRAS* resulted in up-regulation of ERBB2 and ERBB3 expression in human and murine models, which prompted cancer cell utilization of CAF-derived NRG1 as a survival factor. Genetic depletion or pharmacological inhibition of ERBB2/3 or NRG1 abolished KRAS* bypass and synergized with KRAS

Keywords

Humans, Animals, Mice, Proto-Oncogene Proteins p21(ras), Cell Proliferation, Pancreatic Neoplasms, Carcinoma, Pancreatic Ductal, Neuregulin-1

Comments

Supplementary Materials

PMID: 37775182